| Catalog No. | Size | Price (USD) |
| 40588-MM124-20 | 20 µL | $296.22 |
| 40588-MM124-100 | 100 µL | $592.44 |
General Information
| Product name | SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Mouse MAb |
| Validated applications | WB (FAQ Protocol), ELISA (FAQ Protocol), ELISA(Cap) (FAQ Protocol), ELISA(Det) (FAQ Protocol), IHC-P (FAQ Protocol), FCM (FAQ Protocol) |
| Application notes | (Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.) |
| Specificity | SARS-CoV-2 Nucleocapsid Has cross-reactivity in ELISA and WB with SARS-CoV Nucleocapsid Protein (Cat#40143-V08B) Has cross-reactivity in ELISA with SARS-CoV-2 Omicron (B.1.1.529) Nucleocapsid Protein (Cat# 40588-V07E34) SARS-CoV-2 Omicron (BA.2) Nucleocapsid Protein (Cat# 40588-V07E35) SARS-CoV-2 Omicron XE(BA.1 x BA.2) Nucleocapsid Protein (Cat# 40588-V07E36) SARS-CoV-2 Omicron (BA.4) Nucleocapsid Protein (Cat# 40588-V07E37) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (D377Y) Protein (Cat# 40588-V07E16) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (R203M, D377Y) Protein (Cat# 40588-V07E20) SARS-CoV-2 Delta (B.1.617.2) Nucleocapsid Protein (Cat# 40588-V07E29) SARS-CoV-2 Delta (B.1.617.3) Nucleocapsid (P67S, R203M, D377Y) Protein (Cat# 40588-V07E30) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(R203K, G204R) Protein (Cat# 40588-V07E1) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(I292T) Protein (Cat# 40588-V07E4) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, R203K, G204R, S235F) Protein (Cat# 40588-V07E7) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, S235F) Protein (Cat# 40588-V07E8) SARS-CoV-2 Alpha(B.1.1.7/ B.1.237) Nucleocapsid(S194L) Protein (Cat# 40588-V07E3) SARS-CoV-2 Alpha/beta(B.1.1.7/ B.1.351/ A.2.2) Nucleocapsid(P13L) Protein (Cat# 40588-V07E2) SARS-CoV-2 Beta(B.1.351/B.1.351.2/b.1.351.3/B.1.427/B.1.429) Nucleocapsid (T205I) Protein (Cat# 40588-V07E9) SARS-CoV-2 Gamma(P.1/ P.1.1/ P.1.2) Nucleocapsid (P80R) Protein (Cat# 40588-V07E11) SARS-CoV-2 Eta(B.1.525) Nucleocapsid (A12G, T205I) Protein (Cat# 40588-V07E19) SARS-CoV-2 Nucleocapsid Protein (Cat# 40588-V07E) No cross-reactivity in ELISA with MERS-CoV Nucleocapsid Protein (Cat# 40068-V08B) HCoV-229E Nucleocapsid Protein (Cat# 40640-V07E) HCoV-NL63 Nucleocapsid Protein (Cat# 40641-V07E) HCoV-HKU1 Nucleocapsid Protein (Cat# 40642-V07E) HCoV-OC43 Nucleocapsid Protein (Cat# 40643-V07E) |
| Immunogen | Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (Catalog#40588-V08B) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, SARS-CoV-2 (2019-nCoV) Nucleocapsid (Catalog#40588-V08B; YP_009724397.2(335Gly/Ala); Met1-Ala419). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #124 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Image / Experimental Information
| Image 1 Description | Anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid mouse monoclonal antibody at 1:1000 dilution. Lane A: SARS-CoV Nucleoprotein / NP Protein(Cat#40143-V08B)(10ng) Lane B: SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein(Cat#40588-V08B)(10ng) Secondary Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. |
| Image 1 Alt Text | 2019-nCoV Coronavirus Nucleocapsid Western blot (WB) 31565 |
| Image 1 URL | Source image |
| Image 2 Description | Anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid mouse monoclonal antibody at 1:1000 dilution. Lane A: SARS-CoV Nucleoprotein / NP Protein(Cat#40143-V08B)(10ng) Lane B: SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein(Cat#40588-V08B)(10ng) Secondary Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. |
| Image 2 Alt Text | SARS-CoV-2 Coronavirus Nucleocapsid Immunohistochemistry(IHC) 32865 |
| Image 2 URL | Source image |
| Image 3 Description | Anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid mouse monoclonal antibody at 1:1000 dilution. Lane A: SARS-CoV Nucleoprotein / NP Protein(Cat#40143-V08B)(10ng) Lane B: SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein(Cat#40588-V08B)(10ng) Secondary Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. |
| Image 3 Alt Text | SARS-CoV-2 Coronavirus Nucleocapsid Western blot (WB) 32884 |
| Image 3 URL | Source image |
| Image 4 Description | Anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid mouse monoclonal antibody at 1:1000 dilution. Lane A: SARS-CoV Nucleoprotein / NP Protein(Cat#40143-V08B)(10ng) Lane B: SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein(Cat#40588-V08B)(10ng) Secondary Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. |
| Image 4 Alt Text | SARS-CoV-2 Coronavirus Nucleocapsid Flow Cytometry (FC) 32891 |
| Image 4 URL | Source image |
Background Information
| Description | Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. |
| References |
|
title: Utilizing Constrained Bicyclic Peptides for In Vitro Diagnostics
authors: André Shamsabadi; Adam Creamer; ...; Molly M. Stevens
journal: ACS Nano
date: 2026-02-13
pmid: 41685809
cited_by_count: 0
techniques: In Vitro
bioz_score: 93
title: Targeting the liquid-liquid phase separation of nucleocapsid broadly inhibits the replication of SARS-CoV-2 strains
authors: Lin Gu; Zheng-Jie Wang; ...; Wen Xue
journal: Biochemical and biophysical research communications
date: 2025-03-01
doi: 10.1016/j.bbrc.2025.151594
cited_by_count: 0
techniques: Immunoprecipitation; Sequencing; Synthesized; Western Blot
bioz_score: 93
title: Development of a Peptide Aptamer-Based TRFIA for the Quantitive Detection of SARS-CoV-2 Nucleocapsid Protein.
authors: Hongfang Chen; Tonggong Liu; ...; Dayong Gu
journal: Journal of Fluorescence
date: 2025-02-22
pmid: 39985615
doi: 10.1007/s10895-025-04199-w
cited_by_count: 0
bioz_score: 93
title: Endogenous IFITMs boost SARS-coronavirus 1 and 2 replication whereas overexpression inhibits infection by relocalizing ACE2.
authors: Qinya Xie; Caterina Prelli Bozzo; ...; Frank Kirchhoff
journal: iScience
date: 2023-04-21
pmid: 36968088
cited_by_count: 11
techniques: Control; Luciferase; Modification; Purification; Recombinant; Saline; Virus
bioz_score: 93
title: A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 trans -Signaling and Cellular Infection with SARS-CoV-2
authors: Julia Ettich; Julia Werner; ...; Tom Gallagher
journal: Journal of virology
date: 2021-12-22
pmid: 34935434
doi: 10.1128/jvi.01622-21
pmcid: 8865451
cited_by_count: 7
techniques: Concentration Assay; Fluorescence; Immunofluorescence; Infection; Microscopy; Positive Control; Software; Staining
bioz_score: 93
title: Macrophages and Monocytes: “Trojan Horses” in COVID-19
authors: Elena Percivalle; Josè Camilla Sammartino; ...; Oliver Schildgen
journal: Viruses
date: 2021-10-28
pmid: 34834984
doi: 10.3390/v13112178
pmcid: 8624282
cited_by_count: 23
bioz_score: 93
